NRIX vs PFE: Which Is the Better Buy in 2026?

Same yardstick, side by side (as of August 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.

The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. NRIX and PFE share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.

This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined NRIX and PFE exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.

Nurix Therapeutics is a clinical-stage biopharmaceutical company that designs targeted protein degradation medicines, small molecules that harness the body's own protein-disposal machinery to eliminate disease-driving proteins rather than merely blocking them. Its lead program, bexobrutideg (NX-5948), is an oral, brain-penetrant degrader of BTK being studied in chronic lymphocytic leukemia and other blood cancers, with a pivotal Phase 2 DAYBreak CLL-201 study supporting a potential accelerated approval and a Phase 3 DAYBreak CLL-306 study planned to begin around mid-2026. Beyond bexobrutideg, Nurix has wholly owned programs including zelebrudomide (NX-2127) and the CBL-B inhibitor NX-1607, plus partnered discovery work with Gilead Sciences, Sanofi, and Pfizer where it retains options to co-develop and share profits.

Full NRIX guide

Pfizer is one of the world's largest pharmaceutical companies, developing, manufacturing, and selling prescription medicines and vaccines across many therapeutic areas. Its portfolio spans oncology (a strategic priority, expanded sharply by the acquisition of cancer drugmaker Seagen), vaccines (including pneumococcal franchise Prevnar and its COVID-19 vaccine Comirnaty, partnered with BioNTech), internal medicine and cardiology (such as the Vyndaqel/Vyndamax family and Eliquis, co-marketed with Bristol Myers Squibb), immunology and inflammation, and antivirals (including the COVID treatment Paxlovid). Pfizer makes money selling these drugs to wholesalers, pharmacies, hospitals, and governments worldwide. The company saw an enormous revenue surge from COVID-19 products during the pandemic, then a steep decline as that demand normalized, leaving it to refill growth through its pipeline, oncology expansion, and acquisitions while a wave of patent expirations looms later this decade. Founded in 1849 and headquartered in New York City, Pfizer is a mature, dividend-paying large-cap navigating a post-COVID reset.

Full PFE guide

Both fit overlapping themes, but they are not interchangeable. The useful comparison is which set of drivers and risks you want exposure to.

• NRIX drivers: Bexobrutideg pivotal path; Roche collaboration.
• PFE drivers: Oncology expansion via Seagen; Broad, diversified portfolio.

A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. The honest test is which set of risks you could hold through a drawdown: As a clinical-stage biotech, Nurix has no approved product and generates only modest collaboration revenue against large research spending, so it posts substantial net losses and depends on its cash balance and partner payments to keep funding trials. For PFE, pfizer faces a significant patent cliff later this decade, with several major products losing exclusivity, pressuring revenue unless the pipeline and acquisitions fill the gap.

Pick NRIX if you believe its drivers more; PFE if you believe its. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the NRIX and PFE guides.

NRIX. Nurix is pre-profit, so traditional metrics like P/E do not apply; the market values it on pipeline potential, partnership economics, and cash runway. Q1 FY2026 revenue fell sharply year over year as certain Sanofi collaboration research terms wound down, while R&D spending drove a wider net loss. The roughly $540 million cash position funds the registrational bexobrutideg program and broader pipeline, though a quarterly burn near $80 million and future trials mean funding and dilution remain key watch items.

PFE. Pfizer trades at a below-market multiple and a high dividend yield, reflecting investor concern about the post-COVID revenue reset and a looming patent cliff. Its valuation balances substantial cash generation and diversification against questions over whether the pipeline and Seagen-led oncology push can restore durable growth.

Headline figures (approximate, MARCH 2026): NRIX shows revenue (q1 fy2026, quarter ended feb 28 2026) ~$6.3 million, revenue (year-ago quarter) ~$18.5 million, r&d expense (q1 fy2026) ~$84.1 million, net loss (q1 fy2026) ~$87.2 million (~-$0.79 per share); PFE shows revenue (ttm) ~$60 billion, operating margin ~25%, recovering post-COVID normalization, net income (ttm) multi-billion, variable with COVID product swings, dividend yield ~6%, high for large-cap pharma.

NRIX and PFE are related but distinct: same themes, different businesses and risks. Neither wins in the abstract; the right pick is whichever thesis you actually believe, sized so you are not over-concentrated in one theme. Walnut can show your combined NRIX and PFE exposure against your real portfolio. It is not an investment adviser.